Q&A With Matt Oster From Emory University: Finding Best Practices For Screening and Treating Young Cardiac Disease Patients

For children born with single ventricle defects every day matters in getting the treatment and operations they need to survive. A new study looked at a commonly known medication which could help get them extra time for their treatment.

Matt Oster, MD, MPH, from Emory University discussed the study of digoxin and what it could mean for patients during the American Heart Association's annual scientific sessions in Orlando.

Patients born with single ventricle defects often have other conditions and issues to deal with after their birth including neurological disorders. A recent study looked at how common this problem is and what can be done to best address these concerns.

While states around the country screen for critical congenital heart disease how they conduct that screening can vary as much as the states themselves. What that means for overall patient care is a matter of recent discussion in the field.